Orion Clinical Revenue and Competitors
Estimated Revenue & Valuation
- Orion Clinical's estimated annual revenue is currently $94.9M per year.
- Orion Clinical's estimated revenue per employee is $201,000
Employee Data
- Orion Clinical has 472 Employees.
- Orion Clinical grew their employee count by 3% last year.
Orion Clinical's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director, Business Development | Reveal Email/Phone |
2 | Executive Director, Business Development | Reveal Email/Phone |
3 | Senior Project Director | Reveal Email/Phone |
4 | Director Quality Assurance | Reveal Email/Phone |
5 | Chief Commercial Officer | Reveal Email/Phone |
6 | Associate Director Project Management | Reveal Email/Phone |
7 | Associate Medical Director | Reveal Email/Phone |
8 | Project Director | Reveal Email/Phone |
9 | Project Director | Reveal Email/Phone |
10 | Regulatory Affairs Manager | Reveal Email/Phone |
Orion Clinical Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $773.8M | 3120 | 8% | $1.8M | N/A |
#2 | $6.8M | 34 | -11% | N/A | N/A |
What Is Orion Clinical?
Simbec-Orion Group is a full-service, boutique CRO which offers specialist expertise in oncology, rare & orphan diseases, dermatology, respiratory, neurology and infectious diseases and translational medicine. We offer our clients a full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies. We have expertise in all drug types, dosage forms and delivery mechanisms. Simbec-Orion Group supports its clients’ development programmes with our in-house central laboratories, pharmacovigilance, data management and statistics, IMP management/pharmacy and medical management. Rare and Orphan, Oncology, Pharmacovigilance, Phase I-Phase IV, Clinical Research Organisation, Drug Development, Strategic Development and Planning, Regulatory Planning, Oracle Clinical Systems, Biotechnology and Pharmaceutical, FDA, MHRA, EMA
keywords:N/A
N/A
Total Funding
472
Number of Employees
$94.9M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Orion Clinical News
... additional ongoing or planned large clinical studies for darolutamide across ... Darolutamide is developed jointly by Orion and Bayer.
Originally published by our sister publication, Clinical Oncology News. ... Bayer/Orion) to androgen deprivation therapy (ADT) and...
We have promising new research projects for pain management, and we expect to proceed to clinical trials within the next 12 months. We have also...
Clinical trials have evolved from drug- to target-oriented trials, and this shift has raised several challenges. TORONTO, Ontario (PRWEB) June 04, 2021 Genomic sequencing techniques and bioinformatics have led us to a better understanding of cancer biology, resulting in a shift from empirical ...
Proactively planning for additional study elements gives greater flexibility, allowing you to make decisions based on emerging data, without requiring additional regulatory approval. TORONTO (PRWEB) May 12, 2021 In early clinical development, making changes to a study design after regulatory a ...
Other Companies in Slough
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $131.5M | 478 | 27% | N/A |
#2 | $101.5M | 560 | -5% | N/A |
#3 | $219.2M | 575 | -3% | N/A |
#4 | $129.6M | 603 | -1% | N/A |
#5 | $236.8M | 621 | 5% | N/A |